🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This Phase Ib dose escalation study is designed to characterize the safety,...
Status
Completed
Location
Novartis Investigative Site
Start Date
2008-02
Trial ID
NCT00663832
Treatments Being Tested
The primary purpose of this study is to identify the maximum tolerated dose...
Status
Terminated
Location
University of California at Los Angeles
Start Date
2008-04
Trial ID
NCT00567879
Treatments Being Tested
The subjects are being asked to take part in the Phase I or Phase II portio...
Status
Terminated
Location
University of Pittsburgh
Start Date
2009-09
Trial ID
NCT00958022
Treatments Being Tested
The purpose of this study is to investigate the anti-myeloma effect of pano...
Status
Withdrawn
Location
Multiple Locations
Start Date
2016-12
Trial ID
NCT02756663
Treatments Being Tested
This study will characterize the safety, tolerability, biological activity,...
Status
Completed
Location
Novartis Investigational Site
Start Date
2008-07
Trial ID
NCT00739414
Treatments Being Tested
The primary purpose of this study is to identify the maximum tolerated dose...
Status
Completed
Location
Novartis Investigative Site
Start Date
2008-12
Trial ID
NCT00788931
Treatments Being Tested
The purpose of the study is to assess the benefit of panobinostat monothera...
Status
Terminated
Location
UCLA
Start Date
2009-02
Trial ID
NCT00777335
Treatments Being Tested
This Phase II single dose study was designed to characterize the safety, to...
Status
Completed
Location
University of Maryland
Start Date
2008-03-18
Trial ID
NCT00667862
Treatments Being Tested
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) ...
Status
Unknown
Location
Huniversitätsspitals Basel
Start Date
2008-06
Trial ID
NCT01159418
Treatments Being Tested
SCLC is the most aggressive and lethal form of lung cancer, typically very ...
Status
Completed
Location
Klinik für Onkologie und Haematologie
Start Date
2008-05
Trial ID
NCT01222936
Treatments Being Tested